Biomarkers or biological markers are molecules found in blood, body fluids, or tissues that explain what is happening in a cell or organism. They are used to perform clinical assessments and monitor and predict health states in individuals. For instance, high levels of lead in the bloodstream may indicate a need to test for nervous system and cognitive disorders, especially in children. Biomarkers play a crucial role in determining relationships between environmental exposures, human biology, and disease. A biomarker can also act as a diagnostic measure that examines the organ function or other aspects of health when introduced into an organism. Biomarkers can also aid in disease prognosis by providing information about the patient's overall outcome, regardless of any treatment or therapeutic intervention.
The rising incidence and prevalence of chronic disorders potentiates the demand for finding the root cause of the disease and aiding in novel drug discovery and development. The growing research and development boost biomarkers research. The market is also driven by increasing investments from both government and private organizations, and collaborations augment the market.
The biomarkers market size to grow from at US$ 94.32 billion in 2024 and is projected to grow to US$ 366.6 billion by 2034, rising at a double digit compound annual growth rate (CAGR) of 14.54% from 2024 to 2034. The rising incidences of chronic disorders, growing research and development, and increasing investments drive the market.
In January 2025, the fourth quarter (Q4) of 2024, reports were released by Sanofi. There was a rise in the net income, which was reported to be €880m ($916m). €1.06bn was noted to be the company's income before joint ventures, tax, and associates. €1.18bn was achieved as operating income, indicating growth, while €7.84bn was the reported gross profit. €2.25bn were the R&D expenses. Moreover, the net sale was noted to be €10.56bn, which indicated growth.
In October 2024, financial results for the third quarter of 2024 were announced by Regeneron Pharmaceuticals, Inc. The revenues showed a growth of 11% to $3.72 billion. The global net sale of Dupixent® was 23% to $3.82 billion, and for Libtayo® were 24% to $289 million, which reflected overall growth. Whereas, the U.S. net sales for EYLEA HD® and EYLEA® increased by 3%. Moreover, the GAAP diluted EPS and non-GAAP diluted EPS(a) increased by 30% to $11.54 and 8% to $12.46, respectively.
Rinol Alaj, Senior Director of Digital Health Technologies at Regeneron, commented that many companies are working independently on building digital biomarkers. Hence, the company organized the Digital Biomarkers Summit in May 2024, which could be a terrific opportunity to bring the industry together and create a mechanism of collaboration to help accelerate overall digital biomarker adoption. He also explained that researching digital biomarkers requires change management, innovative thinking/frameworks, and novel ways of problem-solving.
In January 2024, Angel Alberich-Bayarri, Co-Founder and CEO of Quibim, announced its collaboration with Merck KGaA, Darmstadt, Germany, to develop the next generation of precision medicine technology targeting a wide range of cancers. Also commented on the partnership that the partnership is poised to be a game-changer in the field of oncology by utilizing their innovative imaging-based methodologies.
Collaborate with our experts to explore the Biomakers Market at sales@towardshealthcare.com
